Viewing Study NCT02583594


Ignite Creation Date: 2025-12-25 @ 1:41 AM
Ignite Modification Date: 2025-12-27 @ 10:08 PM
Study NCT ID: NCT02583594
Status: COMPLETED
Last Update Posted: 2021-03-10
First Post: 2015-10-16
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis
Sponsor: Genzyme, a Sanofi Company
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module